Lysophosphatidic acid receptor (LPAR) modulators: The current pharmacological toolbox. (April 2015)

• Record Type: Journal Article
• Authors: Llona-Minguez, Sabin; Ghassemian, Artin; Helleday, Thomas
• Is Part Of: Progress in lipid research. Volume 58(2015:Apr.)
• Page Start: 51
• Page End: 75
• Publication Date: 2015-04
• Subjects: Lysophosphatidic acid -- GPCR -- Agonist -- Antagonist -- Small molecule -- Idiopathic pulmonary fibrosis -- Systemic sclerosis -- Cancer; Lipids -- Periodicals; Lipids -- Periodicals; Lipides -- Périodiques; Lipiden; 572.57
• DOI: 10.1016/j.plipres.2015.01.004
• Languages: English
• ISSNs: 0163-7827

Abstract

Abstract: Lysophosphatidic acids (LPA) are key lipid-signalling molecules that regulate a remarkably diverse set of cellular events, such as motility, chemotaxis, cell cycle progression, viability, and wound healing. The physiological and pathophysiological consequences of LPA signalling are evident and misregulation of LPA signalling can lead to pathologies like cancer, atherosclerosis, ischaemia, and fibrosis. LPA exerts its biological actions mainly through several types of G protein-coupled receptors, some of which display opposing or redundant effects. For this reason, selective LPA receptor small-molecule ligands can shine light on LPA biology and present an exciting opportunity for drug discovery endeavours. This review provides insights into the detailed chemical nature and pharmacological profile of the small-molecules thus far developed as LPA receptor modulators, as well as information on the preparation of key pharmaceuticals. This summary will facilitate future research efforts and nurture collaboration between chemists and biologists working in this emerging field.